← Home / ARS Pharmaceuticals, Inc. (SPRY)
Stock Analysis
ARS Pharmaceuticals, Inc. (SPRY)
SPRY
SPRY · Market data
5.13 -8.88%
Track SPRY in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when SPRY price is:
52W Range Position
0%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 19:55 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
7.61
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
17
●
Management / Board
MEDIUM
SPRY board and management update
On July 15, 2026, Richard Lowenthal resigned as a member of the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc.
8-K Filing • SEC EDGAR
JUL
7
●
Management / Board
MEDIUM
SPRY board and management update
On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc.
8-K Filing • SEC EDGAR
MAY
15
●
Financial Results
HIGH
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
(Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients against allergic reactions that could lead to anaphylaxis, today announced financial results for the first quarter of 2026 and provided an update on the continued commercialization of...
8-K Filing • SEC EDGAR
What's Driving SPRY?
📈 Technical recovery is improving
Momentum is Neutral. Watch 7.61 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
21.8
Price Chart
SPRY — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$509.4M
Company size
EV
$581.6M
Debt-adjusted value
P/E
-2.6
Not meaningful
P/S
5.1
Balanced
P/B
8.3
Premium
EV/Sales
5.9
Balanced
EV/EBIT
-2.9
Not meaningful
P/FCF
-2.9
Not meaningful
FCF Yield
-34.42%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Stretched
💵 Revenue
22.68M
↗ Strong
📈 Net Income
-60.62M
↘ Negative
🧮 EPS (Basic)
-0.61
↘ Negative
ARS Pharmaceuticals, Inc.
Related Opportunities